IO 2.0

NANJING, China, August 20, 2026 Leads Biolabs announced that the full abstract for its Phase II study of LBL-024...

NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...

NANJING, China, July 30, 2026 Leads Biolabs announced that its Phase II clinical trial evaluating Opamtistomig (LBL-024), a proprietary...